[{"orgOrder":0,"company":"Staten Biotechnology","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"NETHERLANDS","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"SST-5058","moa":"APOC-3","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Staten Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Staten Biotechnology \/ Novo Nordisk","highestDevelopmentStatusID":"6","companyTruncated":"Staten Biotechnology \/ Novo Nordisk"}]

Find Clinical Drug Pipeline Developments & Deals by Staten Biotechnology

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          IMCAS Asia
                          Not Confirmed
                          IMCAS Asia
                          Not Confirmed

                          Details : STT-5058 is a monoclonal antibody that targets the lipoprotein ApoC3 and is being developed in collaboration with Novo Nordisk.

                          Product Name : SST-5058

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          July 21, 2020

                          Lead Product(s) : SST-5058

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase I

                          Sponsor : Novo Nordisk

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank